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1. Introduction
Oxidative stress appears when prooxidant-antioxidant balance is altered in the direction of
the former, causing neuronal cell death and dysfunction, so resulting in oxidative damage
lending to disease pathogenesis. Brain tissue have a very high metabolic rate as it consumes
approximately 20% of the inhaled oxygen due to the fact that neurons need high amounts of
ATP for sustaining ionic gradients across cell membranes and so as for neurotransmission and
as most of the ATP is produced via oxidative metabolism, neurons are dependant on mito‐
chondrial function supremely. Oxidative stress is known to act a part in mitochondrial
dysfunction and brain damage associated with epileptic seizures. In recent studies it is implied
that epileptic status alters the redox potential and diminishes ATP levels creating a break down
in brain energy production and a damage to cellular targets such as protein, lipids and DNA
is seen following persistent seizures. Thus a consecutive cell damage emerges after persistent
seizures with an increase in mitochondrial oxidative stress status in epilepsy patients.
Brain tumours typically cause epileptic seizures. The life quality of patients with brain tumors
having epileptic seizures are seriously effected owing to the factors not being clear and the
problems confronted in the treatment. Antiepileptic treatment culminates with limited success
due to drug interactions, adverse effects and pharmacoresistance frequently.The mechanism
of epileptogenesis in patients having a brain tumour is not clarified obviously yet. Seizures are
conferred as the initial symptom in around 30-50% of patients particularly with slow growing
primary brain tumors [1]. Seizures are mostly seen in patients having low grade tumors while
in patients with high grade brain tumors the insidance is lower. Also, the location of the tumor
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is an important deterministic of epileptic seizures. Due to the decreased intratumoral perfusion
and increased metabolism, hypoxia occurs causing acidosis through metabolic requirements
of the proliferating tissue and the disrupted oxidative energy metabolism, both inducing glial
cell swelling and damage effecting the surrounding tissue [2]. It was implied that derangement
between the excitatory and inhibitory balance leads to glioma associated seizures as there is
an intimate relationship between seizure activity and increased extracellular glutamate levels
in tumor related epilepsy. The involvement of tumor growth is not clear yet. Glutamate levels
are shown to increase reaching neurotoxic levels during seizures. Epileptic activity is implied
to be originating within the peritumoral border distant from the tumor tissue and it was shown
that the glutamate levels were higher in peritumoral cortex when compared with health brain
tissue parts in glioma patients. GABA receptor activity is thought to be an inhibitor as receptor
down regulation seems causing hyperactivity in the surrounding microenvironment. There is
also a close relationship between immunological and inflammatory changes with a diminished
risks of glioma and epileptic seizures related to tumor presence as proinflammatory cytokines
seem to be involved in epilepsy pathogenesis [3,4]. On the other hand, patients having epileptic
seizures with brain tumors were reported having increased levels of ROS and the antioxidant
status was found to be decreased. This seems to be recovered after treatment with antiepileptic
drugs favoring the so called damaging effect of oxidative stress in epilepsy flashing the
estimated possibility of preventing the seizures via antioxidant treatment. Alleviation of the
oxidative damage utilizing antioxidant substances in epilepsy was shown experimentally.
These knowledge may highlight the possible future strategies in the medical treatment of
tumor associated epilepsy. In terms of surgical aspects, removing the tumor to stop epileptic
seizures might not assure a prosperous result alone considering that the neurons surrounder
the tumor form an epileptogenic area [2]. On the other hand, when the lesion is removed,
surrounding neurons may stop exciting aberrantly, returning to normal status. Thus the
neurosurgeons are suggested to minimize the residual tumor volume where applicable. The
conservation of the mitochondria and eventually decreasing oxidative stress related events
seems to be reasonable therapeutic approach. Not only resecting the tumor but also combining
an appropriate postoperative treatment should be the main aim in seizure control. As men‐
tioned, therapy with antioxidants having a potential neuroprotective effect, should be
intended to lower the conferred oxidative damage in epilepsy treatment where ketogenic diets
were also shown to have beneficial effects in treating epileptic seizures as they seem to increase
glutathione levels in mitochondria. It is clear that developing a mitochondria targeted
antioxidant therapy would be promising approach in epilepsy, hopefully resulting in seizure
control withdrawing treatment with antiepileptic drugs in long term.
2. The biochemical mechanisms transpiring in case of epileptic seizures
Epilepsy should be considered not only as a single disease, but also common symptomatic
symptoms of brain abnormalities involving central nervous system infections, traumatic brain
injuries, genetic syndromes or brain lesions such brain tumors are present. The relationship of
inflammation in the pathophysiology of epilepsy is implied in various clinical studies [5,6].
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The dysregulated homeostasis in the peritumoral tissue may cause to seizure somethesia as
the tumor cells create an intrinsic epileptogenicity. The most vital mechanism inducing tumor
related seizures is the alteration of amino acid neurotransmission where also an alteration in
the extracellular ions is involved. These mechanisms should be enlightened to provide
guidance for improving new strategies in the surgical and medical treatment for tumor
associated epilepsy.
The tumor tissue might be epileptogenic due to excreting some molecules itself or the peritu‐
moral tissue might be transformed into an epileptogenic zone as the microenvironment of
brain tumors is considerably different from that of healthy brain tissue which is demonstrated
via contemporary imaging techniques. On the other hand, the peritumoral tissue might turn
into an epileptogenic zone because of the mechanic restrainment of the tumor as a result of
hypoxia and ischemia. These lead to epileptic seizures following the alterations in neurotrans‐
mitters and their receptors, metabolic changes and inflammatory responses. Structural
epileptogenic abnormalities in the cortex might also be attended as low levels of N-acetylas‐
partate which is a marker for the survival and functionality of the neurons, was shown in the
epileptogenic cortex via magnetic resonance spectroscopy [7]. It was shown that damage in
the subcortical network affecting the electrical transmission is effectuated mostly by high grade
brain tumors [8] while a partial deafferentation in cortical regions is induced by low grade
tumors causing an epileptogenic stage [9,10]. Inflammatory changes and gliosis in the
peritumoral tissue also contribute. Derangements in the neurovascular entirety also cause
hypersynchronization leading to epileptogenity. The emerge of decreased expression of
junctional transmembrane proteins [11] and increased vascular endothelial growth factor
(VEGF) release which aggrevates the edema in the surrounding of the lesion [12] is due to the
impaired blood brain barrier through molecular alterations in brain tumors and hypoxia and
acidosis, appearing sequentially, occur because of the enhanced metabolism and the dimin‐
ished perfusion in the intratumoral tissue. Definitely, an adequate blood supply is obligatory
for brain tumor growth [13] and in case of inadequate blood supply, acidosis followed by
interstitial hypoxia appears extending to the surrounding tissue, as a consequence of both
elevated metabolic requirements of the proliferating tissue and impaired oxidative energy
metabolism. Also, peritumoral hypoxia comes out because of direct restrainment through large
sized tumors. In either case, damage sequential to glial cell swelling occurs [14] where the
membranes of the cells are vulnerable for inward sodium currents augmenting the risk of
epilepsy [15]. In consequence of hypoxia, glucose catabolism picks up culminating excess
lactate production which leads to acidosis and in tumor tissues increased lactate levels were
also shown [16]. In the peritumoral area the increase in sodium and calcium levels contribute
to neuronal hyperexcitability [17] and the change in the gating of calcium channels have been
reported in epileptic tissue where calcium influx is blocked via NMDA receptor channels
through stabilizing the neuronal excibility by magnesium. Also, mutations in the potassium
channels were implied and the extracellular potassium concentrations are known to play a
role in membrane potential [18,19].
Glutamate is an excitatory neurotransmitter which acts on postsynaptic membranes through
interacting with ionotropic and metabotropic glutamate receptors [20]. There is a relationship
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between seizure activity and high levels of extracellular glutamate in tumor associated
epilepsy. Increased levels of glutamate was shown in glioma patients with epilepsy [15,21].
The number of glutamate receptors are variable depending on the tumor degree. Ionotropic
glutamate receptors, which induce intracellular calcium release when activated, are NMDA,
AMPA and kainate receptors and with marred activity, in the peritumoral tissue differences
in the expression are seen. GABA is also a neurotransmitter which inhibits neuronal discharge
and when there is a down regulation in GABA receptors, which are GABAA, GABAB and
GABAC, hyperactivity in the peritumoral zone is encountered. Alterations in the functions of
GABA receptors in the peritumoral tissue, induce GABAergic neurotransmission alleviation
and GABA levels are reported to be increased in tumor tissues [18,19]. GABAergic activity
doesn’t have a relationship with seizure somethesia directly yet the alterations in the levels
seem causal for tumor related epilepsy. Also, in gliomas decreased kynurenic acid levels
causing NMDA receptor disinhibition [22] and decreased noradrenaline and serotonin levels
causing antiepileptogenic effects were reported [23].
Inflammation, either immune mediated or without infection, also play a crucial role in epileptic
seizures and in tumor related epilepsy where proinflammatory cytokines being inflammatory
mediators and their receptors are involved in the pathogenesis. High levels of cytokines such
as interleukin (IL)-6, IL-1β and the IL-1, tumor necrosis factor (TNF)-α were implied [24].
Cytokine activation depends on both seizure severity and duration in epilepsy patients. [25,
26]. Activation of IL-1β system in glial cells expressing IL-1β and its receptor was reported in
studies with chronic epileptic rats [27,28]. IL-4 and IL-6 were shown to be having modulating
effects on neurotoxic neurotransmitters which are released during excitation and inflammation
[29]. In the peritumoral tissue neurochemical alterations, coupled with the imbalance between
stimulatory and inhibitory cytokines, which are immune mediated were shown in glioma
[30-32] and reported to be related with tumor associated epilepsy. The activation of toll like
receptor (TLR) signaling pathways, which are activated via pathogens or endogenous ligands
released by damaged or stressor activated cells called as danger signals, is also a current subject
in epilepsy [33,34] and in neurons and astrocytes TLR4 overexpression was demonstrated in
chronic epileptic mice [33,35]. The inflammation in the brain tissue is thought to be contributing
to the deterioration of the blood brain barrier leading to serum albumin and IgG accumulation.
Albumin was reported to be inducing the long lasting hyperexcitability via impairing astrocyte
buffering capacity of extracellular potassium and glutamate through activating transforming
growth factor (TGF)-β pathway which leads to glutamate transporter downregulation [36-38].
These induced mechanisms through brain inflammation might explain the detention time
occuring between the inflammatory complications and the inception of epilepsy.
3. The redox status in brain tumors
Brain is considered to be intensely vulnerable to oxidative damage having a high content of
peroxidizable unsaturated fatty acids, high oxygen consumption per unit weight, high content
of iron which is a key in lipid peroxidation and a shortage of antioxidant defense systems [39],
so a crucial and unique target for both oxidative stress effects compared to other tissues and
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for metastatic growth being surrounded by the blood brain barrier. Reactive oxygen species
(ROS), or free radicals, may exceed the scavenging ability of endogenous antioxidants,
resulting in a shift of the redox state of the brain to the oxidative state. Redox balance in neural
tissue has an important role in the pathophysiology of neurotoxicity through the free radical
generation. ROS are particularly active in the brain and neuronal tissue and very aggressive
to glial cells and neurons. Endogenous antioxidant system plays a constitutive role in preven‐
tion of any damage due to free radicals. However, imbalanced defense mechanism of antiox‐
idants, overproduction or incorporation of free radicals from environment to living system
bring about a serious infliction and therefore to a neuronal death [40].
Tumor cells frequently demonstrate a change in redox status. The alterations in the redox
environment enhancing oxidation can induce some of the factors that cause cell proliferation
and malignant transformation. Cancer cells display increased glycolysis rate combined with
a reduced respiration rate [41]. The enhanced requirements for ATP; generates oxygen free
radicals and this causes oxidative stress conditions to come out which eventually promotes
cell death. Neurons and cancer cells consume glucose as energy source to respond this issue
and glycolytic metabolism rules over in tumor cells. The release of cytochrome c couples with
the pentose phosphate pathway and this initiates cytochrome c mediated apoptosis [42].
Caspase activation is initiated by cytochrome c when released from mitochondria during
apoptosis. So, the cancer cells and neurons control apoptosis through regulation of cytochrome
c release, while utilizing glucose as a source of energy [43]. This marked changes in metabolism
have been shown to be related with increased oxidative stress which is emphasized to be due
to increased mitochondrial superoxide radical production [44].
Studies have been done to evaluate antioxidant enzyme activities in different types of brain
tumors. However, most studies have emphasized decreased levels of antioxidant enzymes and
vitamins in diverse malignancies but still the results are inconsistent. Elevated manganase
superoxide dismutase (MnSOD) activities were shown in the serum samples of neuroblastoma
patients in a study. In recent studies, MnSOD was found to be associated with loss of differ‐
entiation and increased clinical malignancy in neuroepithelial origined brain tumors. MnSOD
was found significantly positive in Grade IV astrocytomas and medulloblastomas and negative
in normal brain samples. It can be said that MnSOD is overexpressed in most brain tumor types
and enhanced MnSOD expression is related with a poor prognosis. MnSOD seems to be a
tumor suppressor in the proliferative stage. When tumor progresses more aggressive, MnSOD
is upregulated. MnSOD level positively correlates with increased metastasis so MnSOD has
an oncogene role. Increase in MnSOD level was seen during the progression of different types
of tumors, including brain, to the metastatic stage. Tumorigenesis and metastasis are depend‐
ent on the levels of ROS. A cell having low levels of MnSOD is vulnerable to oxidative stress
then it may turn its progression to a tumor cell. Oxidative gene polymorphism and brain tumor
risk seems to be associated, the increased risk of glioma and meningioma type brain tumors
were found to be related with variants in some antioxidant enzyme genes and in a study,
MnSOD tissue expression is said to be a prognostic marker for glioblastoma. Superoxide
dismutase (SOD) and glutathione peroxidase (GPx) activities showed a clear decrease pro‐
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portionally with tumor malignancy, decrease of SOD activity with the increasing grades of
malignancy in brain tumors were implied [45,46].
The GSH redox cycle is one of the most important antioxidative systems. GSH is a primary
endogenous neuroprotectant for the brain. GSH protects neuron cells from lipid peroxidation
and brain cells from peroxynitrite mediated oxidative damage. GSH is prevalantly seen in
brain tissue, thus highly expressed in various primary brain tumors. GSH content was shown
to be related to tumor response to nitrogen mustard therapy in human brain neoplasms. When
glutathione-S-transferase (GST) isoenzymes in neoplastic and non-neoplastic astroglia were
compared, GST3 isoenzyme was seen to be significantly higher in tumors. It is said that GST
expression levels in brain tumors seems in association with the tumor histology as some tumor
types express enhanced levels but some show only slight rise or decrease when compared to
normal cells. GST was found to be active in high levels in benign tumors such as meningioma
but only two-three folds higher compared to normal tissue but it was slightly increased in
astrocytoma. In glioblastomas, GSH levels were found significantly lowered compared to
normal tissue and merely elevated in meningioma. It has been reported that GPx and gluta‐
thione reductase (GR) enzyme activities decrease and protein oxidation levels increase in
patients with glioblastoma multiforme and transitional meningioma; the two kinds of tumors
which represent specially one of the most malignant and most benign tumors respectively and
it was shown that there is a complex relationship between pro-and anti-apoptotic molecules
in glioblastoma multiforme pathogenesis, thus targeting multiple pathways with advanced
chemotherapeutic agents or radiotheraupetic regimens following total resections might be
helpful in patients with glioblastoma multiforme and consistent differences in the levels of
antioxidants in different types of brain tumors were emphasized in different studies. The
decreased antioxidant levels in brain tumor patients reflect the enhanced oxidative damage
and increased cancer developing possibility, stating the role of antioxidants in cancer preven‐
tion and role of oxidative injury as the of cancer. It was seen that β-carotene and α-tocopherol
levels decreases when malignancy grade increases and the decrease was found significant for
oligodendroglioma grade I-II, glioblastoma multiforme and medulloblastoma [45,46].
4. The pivotal role of oxidative stress during epileptic seizures
Epilepsy, being an excitotoxic brain disorder, causes neuronal destruction incrementally. The
generation of ROS is distinctly implicated in a number of neurologic diseases including seizure
disorders. Oxidative stress and mitochondrial dysfunction are indicated to be having a crucial
role in the pathogenesis of epilepsy [47,48], contributing to the neuronal destruction through
the activation of proapoptotic transcription factors [49,50]. Neuronal cell damage develops due
to recurrent or obstinate seizures and abnormal increases in by products during seizures
through the increased metabolic activity producing ROS with damage and leading to disrup‐
tion of electrophysiologic integrity and instability of neuronal membranes. Fe3+induces
oxidative damage to neuronal plasma membranes and experimentally it was shown that this
is related with the development of epileptic activity. Due to small bleedings, Fe3+levels may
increase in tumoral and peritumoral areas which also prospectively contribute to the devel‐
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opment of tumor related seizures and this is mostly encountered in high grade gliomas [2]. In
an experimental study, intracortical injection of Fe3+induced the formation of epileptic areas
in cerebral cortex. Also, increase in the peroxidation of membrane lipids is found to be related
with the development of epileptic activity [51].
Mitochondrial dysfunction is associated with epilepsy and this was demonstrated both in
humans [52,53] and in several experimental epilepsy models [54,55]. When complex I was
inhibited, markers of oxidative damage; 3-nitrotyrosine, 4-hydroxynonenal and protein
carbonyl levels were significantly increased and this was alleviated treating with a radical
scavenger and an antioxidant enzyme [56,57]. It is suggested that the reduced activity of
complex I is due to oxidative modification with an extreme sensitivity to ROS, on the other
hand complex I is also an important source of ROS, especially when the enzyme complex is
partially inhibited [58,59]. Thereby, when complex I is inhibited, enhanced production of ROS
might lead to epileptogenesis [60]. The pivotal role of mitochondrial dysfunction in the
pathogenesis of epileptic seizure generation seems to be the main topic appraising oxidative
stress.
5. Contributing mitochondrial alterations
Seizure activity is considered to be inducing energy failure and leading to neuronal injury.
Neuronal mitochondria, moving along axons and dendrites, are substantially dynamic [61].
Ca2+regulation, redox signaling, developmental and synaptic plasticity are among the func‐
tions of mitochondria [62].The triggering influence of several mutations in the genes affecting
oxidative phosphorylation in epilepsy implies the importance of mitochondria for neurons.
The related mutations were demonstrated in the mitochondrial DNA polymerase γ (POLG1)
[63,64], mitochondrial tRNALys (MT-TK) [65,66] and tRNAPhe (MT-TF) [67] genes in different
phenotypes of epilepsy. Epilepsy is also appelled as a nonsyndromic mitochondrial disorder
(MID) due to a novel classification and has a genetic or metabolic ground through a cerebral
lesion or dysfunction [68]. Depending on the selection of MID patients, the prevalence seems
to be lower in adulthood and the generalized seizures are remarkably more often compared
to focal seizures.
Decreased ATP levels, changes in neuronal calcium homeostasis and modifications of ion
channels and neurotransmitter transporters due to ROS damage are the main causes of
impaired mitochondrial function and the increased neuronal excitability leading to epilepto‐
genesis. In many studies, ATP depletion during seizures was indicated [69-71] entailing a
decrease in neuronal plasma membrane potential leading to an increase in neuronal excitability
as the major source of ATP for sodium potassium ATPase is the mitochondrial oxidative
phosphorylation in neurons [72,73]. The interneurons, being mithochondria rich, expose a
decreased synaptic transmission in inhibitory synapses, thereby the increased excitability in
epilepsy due to mitochondrial dysfunction could be explained accordingly.
Mitochondria have a substantial role in intracellular Ca2+sequestration in neurons so can be
named as major calcium buffers [74,75]. Attributing to remarkable calcium flow in neuronal
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excitability, through ligand gated and voltage gated ion channels, cyclic calcium elevations
are seen during epileptic activity. Referring to this, mitochondria can attenuate the altered
neuronal excitability and synaptic transmission in epilepsy [76]. Yet another reason for the
increased excitability encountered in epilepsy is, astroglial and neuronal glutamate transport‐
ers’ being quite sensitive to oxidative damage which are known to be crucial for the mainte‐
nance of low synaptic glutamate levels [77]. and it was indicated that complex I activity induces
the excess release of glutamate [78]. So it can be concluded by stating that oxidative stress has
direct effects on neuronal excitability in the same time.
6. Surgical approach
The majority of surgical series showed that almost 60 to 90% of supratentorial benign gliomas
present with epilepsy and surgical resection may be the only treatment option for both
histopathological diagnosis and treatment [79]. There is still discussion whether epilepsy is a
specific property of the tumor or the brain's reaction to the tumor. However, proximity to the
functional areas such as primary motor strip or language or Broca’s area increases the chance
of having seizures. Advanced developments in the imaging technology, brain tumors,
especially low-grade gliomas which were missed in the past, led the physicians to diagnose
such lesions and early surgery is now performed without doubt. Since these gliomas are slow
growing, seizures may occur late and any seizure in the adult life must raise the suspicion of
a tumor until proven otherwise. Magnetic resonance imaging (MRI) is the gold standard
diagnostic modality to diagnose brain tumors and sensitivity is higher than computerized
tomography (CT). Especially T2-weigted and FLAIR images (Figure 1) are important for
visualize low grade tumors which are generally not enhanced with contrast agent. Additional
imaging modalities such as MR spectroscopy may provide further evidence of the lesions true
nature. In some patients electroencephalography (EEG) is needed because of discordant
finding between the MRI and seizure semiology but there is no characteristic EEG pattern.
However; EEG can lateralize the tumor in 70% of patients. Rarely, intracranial depth electrodes
and/or electrocorticography (EcOG) is needed before and during surgery to expose the
epileptogenic area. The most common location for these gliomas is the frontal lobe, followed
by parietal, temporal lobes and insula. Occipital lobe alone is less involved and the reason is
not clear.
Clinical experience has demonstrated that surgical removal of the lesion alone significantly
reduces seizure frequency. It is interesting to note that lesionectomy alone or lesionectomy
with corticectomy show similar good results so that there has been no standard resection
among the centers. But we know very well that completeness of tumor removal is the most
important prognostic factor for seizure control, recurrence, and improved quality of life.
Surgical approach depends mainly on the proximity to the functional cortices which necessi‐
tated local anesthesia (awake craniotomy). On the other hand, when a tumor is located in silent
area, general anesthesia is preferred.
Scalp incision and craniotomy is planned according to the location of the tumor and “question
mark” incision has been extensively used for temporal, frontal tumors (Figure 2). For central
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and parietal located tumors an inverted”U-shaped” incision is usually sufficient. Particular
attention should be paid to dural sinuses and large cortical veins when removing the bone flap
and opening the dura. If awake craniotomy is performed, cortical mapping with intraoperative
electrical cortical stimulation in order to figure out the functional area should be performed.
The aim of the cortical mapping is to have maximum tumor removal with minimum neuro‐
logical deficit by not causing any damage to the functional cortex (Figure 3).
Figure 2. The picture showing a “question mark” scalp incision which is the commonest incision type used in the neu‐
rosurgical operations.
 
(a) (b) 
Figure 1. This 27-year-old male was presented with complex-partial seizure and MRI showed a mass in the left tempo‐
ral lobe without involvement of the mesial temporal structures (hippocampus, parahippocampus and amygdala). The
tumor margin is clearly seen in the preopretive T2-weighted image (a) and histopathological diagnosis was astrocyto‐
ma grade-II and 3 years after the surgery the T2-weighted image (b) shows no tumor recurrence and the patients is
seizure free without antiepileptic medication.
Biochemical and Surgical Aspects of Epilepsy Related to Brain Tumors — Appraising Redox Biology and Treatments
http://dx.doi.org/10.5772/58343
113
 (a) (b) 
Figure 3. This picture shows an awake craniotomy and intraoperative electrical cortical stimulation (cortical mapping)
for the identification of the motor cortex (white paper marks) which is close to the tumor (black dots depict the tu‐
mor) (a). The tumor was removed without any motor deficits (b) and the patient is seizure free at 1 year follow up.
The main surgical technique for the removal of these gliomas is “endopial” resection. By doing
this technique, vessels running deep in the sulci and neighboring cortices are saved. Since these
tumors are surrounded by the pial layers, respecting the pia avoids severe neurovascular
damage during surgery and minimizes postoperative neurological deficits.
7. Potential neuroprotective and therapeutic strategies in tumor related
epilepsy
Epileptic seizures related to brain tumors generally expose kind of focal seizures and around
one third of the patients are resistive to medical antiepileptic treatment. Generally, neuronal
voltage gated sodium and calcium channels, glutamate receptors and the GABA system are
the main targets for antiepileptic drugs (AED) [80] which usually trend to treat through several
mechanisms suppressing abnormal neuronal set off, solely none of the medications seems to
be exhibiting an alteration neither in the progress of the disease not in the prevention [81] due
to a number of reasons involving the biochemical context of the peritumoral zone and the drug
drug interactions between the chemotherapeutics and AEDs inspiring an antiepileptic
effectiveness revealing some side effects [82]. Also, the overexpression of the multidrug
resistance proteins (MRPs) in tumors may restrict medicine diffusion into the brain as
increased levels of MRPs were reported in brain tumor cells [82]. AEDs are known to be leading
to cognitive impairment [83]. Moreoever, some patients under AED therapy exhibit poor
seizure control as well as with undesireable side effects [84] embracing a high risk of terato‐
genicity in women [85], alterations in mood, hepatotoxicity, decrease in the mineral density of
the bone, difficulties in weight management, dermal maladies etc. [86], thereby an increased
tolerability towards new desiged AEDs should be the main intention in future studies.
Currently, development of novel glial specific AEDs is considered to be a potential target
promising to improve a good outcome.
Obviously, epileptogenesis is intimately associated with oxidative stress inducing ROS
generation thus leading to membrane lipid peroxidation and impairment in the antioxidant
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defense system which also increase the risk of seizure recurrence [87]. In case, treatment with
antioxidants is considered to be very profitable in inhibiting epileptic seizures without any
adverse effect [88]. Selenium, an antioxidant protecting against ROS, is known to be causing
an alteration in the rate of some neurotransmitters when deficient and depletion in selenium
levels was reported to be leading to a failure in response to AEDs which act through GABAer‐
gic receptors due to an increased glutamate receptor activation [89] and utilization of selenium
supplements reduce epileptic seizures [90]. Application of resveratrol, a meritorious antioxi‐
dant, was also demonstrated to be useful in seizure management and in reducing seizure
incidence [91]. Similar findings were indicated experimentally where the prevention of
seizures was concerned [92,93] Thymoquinone, another potent free radical and superoxide
radical scavenger, exhibited an antiepileptic effect in children suggesting a lack of adverse
effects even at high doses [94]. With respect to this point of view, the antiepileptic effect of
curcumin, which is an active polyphenolic component, extracted from Curcuma longa called as
turmeric, was also investigated being almost ten times more active than vitamin E as an
antioxidant [95]. Implementation of curcumin which inhibits the transcription of inflammatory
cytokines via nuclear factor kappa B (NF-κB),inducible nitric oxide synthase (iNOS), and
cyclooxygenase 2 (Cox-2) [96], was demonstrated to be preventing the cognitive decline related
to traumatic brain injury [97] and its antiepileptic potential was ascertained with short term
treatment. Recently, inhibitors of mammalian target of rapamycin (mTOR), including rapa‐
mycin and its analogs, are pointed out and regular treatment with rapamycin is emphasized
in preventing epileptogenesis experimentally [98,99], thereby, research relevant to inhibiting
mTOR activity seems appreciable. Curcumin is also suggested as mTOR inhibitor suppressing
epileptogenesis in experimental studies [100,101].
The ketogenic diet (KD), a subdued carbohydrate diet, is known to be effective in epilepsy
treatment [102-104] being neuroprotective and antiepileptogenic. In children, seizures owing
to GLUT-1 and pyruvate dehydrogenase deficiency are treated with KD [105], also a prosper‐
ous outcome is seen with other pediatric epilepsy syndromes [106] as it upregulates the
neuronal gene expression of the enzymes in Krebs cyclus, oxidative phosphorylation and
glycolysis and increases mitochondria density leading to enhanced brain metabolism
[107,108], therefore, stimulating the Krebs cyclus seems to be an attractive strategy in seizure
management via direct replenishment of energy substrates [109,110]. β-hydroxybutyrate,
being a ketone body, protects against metabolic and excitotoxic insults in organotypic
hippocampal cultures [111]. Considering the nutrient and energy sensing ability of mTOR, it
has a role in pathophysiologic changes related to epileptogenesis and mTOR activity is
increased after epileptic status. KD reducing the insulin levels [112], is expected to be inhibiting
mTOR activity through decreasing the PI3K/Akt signaling pathway. Also, ROS have a role in
the efficacy of KD as the production of some mitochondrial uncoupling proteins are increased
with KD and this eventuates with a reduction in the mitochondrial membrane potential and
an increase in mitochondrial respiration rate [113]. Mitochondrial production of ROS is
decreased with ketone bodies via increasing NADH oxidation without affecting endogenous
antioxidant glutathione levels [114]. It was shown that in rat neocortical neurons, ketones
prevent oxidative injury via decreasing mitochondrial ROS production [115]. Recently,
pyruvate seems to be a promising substrate on seizure activity due to its dual action as a
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scavenger of ROS and a substrate of Krebs cyclus, so as a strategy in treatment, this might be
taken into consideration in prolonged seizures [116]. Restricted KD was implied to be an
alternative approach in brain cancer management also, with the purpose of changing the
metabolic environment of the tumor [117], yet further studies are essential in case the glucose
levels of the patients are lowered when simultaneously the ketone levels are elevated, in the
lack of radiation or drug toxicity.
Currently, the role of microRNAs (miRNA) is emphasized in the regulation of immune
responses. miR-146a, known to be induced via several proinflammatory cytokines such as
IL-1β and TNF-α, was shown to be upregulating in experimental epilepsy models [118,119],
thereby miRNA is suggested to be a potential target in modulating the inflammatory path‐
ways. Some inflammatory mediators have direct effects on neuronal excitability providing a
decrease in seizure threshold which was demonstrated experimentally, so if the activation of
inflammatory signalings might be blocked, this may also be appraised as a possible therapeutic
approach for epilepsy patients.
Distinctive medications exhibit variable therapeutic approaches for epilepsy patients. Not only
improving seizure management but also preventing epilepsy in patients who have high risk
should be the main target in the treatment with antiepileptogenics. Future studies are truly
required with an acceptable safety profile, especially for herbal and supplemental products as
there is an incompetence of relevant clinical results although they are recommended in seizure
treatment. Yet, antioxidant compounds, particulary targeting mitochondria, may have
beneficial effects on long term consequences of epilepsy.
8. Conclusion
Epileptic seizures are common in patients with brain tumors. The mechanisms laying beneath
the pathogenesis of tumor related epilepsy remain substantially unclear. Epileptogenicity
might be generated by the tumor itself because of the intrinsic characteristics or the impaired
balance between excitation and inhibition arising due to insufficient homeostasis in the
peritumoral zone might be the reason where also metabolic, immunological and inflammatory
alterations might be contributing. Thereby, clarifying both tumoral and peritumoral patho‐
physiology would lead in selecting the most convenient medical treatment. Recently, oxidative
stress is suggested to be having a crucial role in brain tumor associated epileptic seizures as a
means of mitochondrial dysfunction. Yet it should be enlightened with future studies weather
treatment with antioxidant compounds would be beneficial on attenuating epileptic seizures.
On the other hand, as there are no detectable inflammatory biomarkers with proven signifi‐
cance for epilepsy yet, the challenge should also be defining specific biomarkers which would
be helpful in the diagnosis of antiinflammatory or immunomodulatory therapy effects.
Apparently, bringing novel concepts out in the treatment strategies for brain tumor related
epilepsy should be the main target in the future.
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